Bannerbild German Brest Group

GBG presentations at SABCS

06.12.2019

GBG presentations at SABCS

We are happy to present our contributions at the San Antonio Breast Cancer Symposium 2019.

  1. Jenny Furlanetto, Volker Möbus, Andreas Schneeweiss, Kerstin Rhiem, Hans Tesch, Jens-Uwe Blohmer, Kristina Lübbe, Michael Untch, Christoph Salat, Jens Huober, Peter Klare, Rita Schmutzler, Fergus J Couch, Bianca Lederer, Bernd Gerber, Dirk-Michael Zahm, Ingo Bauerfeind, Valentina Nekljudova, Claus Hanusch, Christian Jackisch, Theresa Link, Sibylle Loibl, Peter A. Fasching Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT) P6-10-03 Poster

  2. Marion van Mackelenbergh, Fenja Seither, Volker Moebus, Joyce O’shaugnessy, Miguel Martin, Heikki Joensuu, Michael Untch, Ulrike Nitz, Juan José Miralles, Masakazu Toi, Harry D. Bear, Hyman Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients GS1-07 Oral
     presentation slides

  3. Jens-Uwe Blohmer, Theresa Link, Sherko Kümmel, Michael Untch, Marianne Just, Peter A. Fasching, Andreas Schneeweiss, Pauline Wimberger, Oliver Stötzer, Jens Huober, Marc Thill, Christian Jackisch, Kerstin Rhiem, Claus Hanusch, Carsten Denkert , Knut Engels, Valentina Nekljudova, Sibylle Loibl Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study GS3-01 Oral
    presentation slides

  4. Karolin Froehlich, Torsten Plösch, Fenja Seither, Volkmar Müller, Thomas Karn, Elmar Stickeler, Christian Schem, Christine Solbach, Amelie Lupp, Rikst Nynke Verkaik-Schakel, Gitta Turowski, Peter Mallmann, Marion van Mackelenbergh, Bruno Sinn, Valentina Nekljudova, Carsten Denkert, Pamela Schittler, Udo Markert, Sibylle Loibl Histological and epigenetic analyses of placenta tissue from breast cancer patients and healthy participants P4-04-08 Poster

  5. Peter A Fasching; Carsten Denkert; Stephen Benz; Karsten Weber; Christopher Szeto; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch; Christian Jackisch; Thomas Karn; Hans Peter Sinn; Mathias Warm; Marion van Mackelenbergh; Sharooz Rabizadeh; Christian Schem; Ernst Heinmöller; Volkmar Müller; Frederik Marmé; Patrick Soon-Shiong; Valentina Nekljudova; Michael Untch; Sibylle Loibl Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - an analysis of the GeparSepto trial PD5-08 Poster discussion (Spotlight session)

  6. Christopher Szeto; Carsten Denkert; Peter A Fasching; Stephen Benz; Karsten Weber; Jan Budczies; Andreas Schneeweiss; Elmar Stickeler; Sabine Schmatloch; Christian Jackisch; Thomas Karn; Hans Peter Sinn; Mathias Warm; Marion van Mackelenbergh; Shahrooz Rabizadeh; Christian Schem; Ernst Heinmöller; Volkmar Müller; Frederik Marmé; Patrick Soon-Shiong; Valentina Nekljudova; Michael Untch; Sibylle Loibl Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations P6-10-04 Poster

  7. Terence Williams, Andreas Schneeweiss, Christian Jackisch, Changxian Shen, Karsten E. Weber, Peter A Fasching, Carsten Denkert, Jenny Furlanetto, Ernst Heinmöller, Sabine Schmatloch, Thomas Karn, Christopher Szeto, Marion van Mackelenbergh, Valentina Nekljudova, Elmar Stickeler, Patrick Soon-Shiong, Christian Schem, Barbara Fleige, Volkmar Müller, Frederik Marmé, Michael Untch, Sibylle Loibl Caveolin Gene Expression Predicts for Response and Clinical Outcomes of Patients Treated with Preoperative Paclitaxel-based Chemotherapy Regimens in Early Stage Breast Cancer P1-10-01 Poster

  8. Sibylle Loibl, Michael Untch, Marc Buyse, André Robidoux, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Joseph Costantino, Pinuccia Valagussa, Colin Neate, Richard Gelber, Coralie Poncet, Pierre Squifflet, Everardo Saad, Dominik Heinzmann, Carsten Denkert, Charles E. Geyer, Jr. , Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Gunter von Minckwitz, Norman Wolmark, Patricia Cortazar, on behalf of the CTNeoBC project Pathologic complete response (pCR) and prognosis in the neoadjuvant therapy of HER2-positive early breast cancer (EBC) P5-06-02 Poster

  9. Charles E. Geyer, Jr, Sibylle Loibl, Priya Rastogi, Sabine Seiler, Joseph P. Costantino, Valentina Nekljudova, Patricia Cortazar, Peter C. Lucas, Carsten Denkert, Eleftherios P. Mamounas, Christian Jackisch, Norman Wolmark A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze OT2-04-08 Poster (ongoing trial)

Indirekte Beteiligung

  1. Cuzick J, Sestak I, Forbes J, Dowsett M, Cawthorn S, Mansell R, Loibl S, Bonanni B, Howell A, IBIS-II investigators. Ten year results of the international breast cancer intervention study II GS4-04 Oral

  2. Kolberg-Liedtke C, Kolberg H, Krajewska M, Bauerfeind I, Fehm T, Fleige B, Helms G, Lebeau A, Staebler A, Loibl S, Untch M, Kühn T. Axillary conversion rates according to breast cancer subtype among patients with pathological complete remission (pCR) in the breast after primary systemic therapy (PST) - A transSENTINA subproject P1-20-02 Poster

  3. Mano MS, Loibl S, Mamounas EP, von Minckwitz G, Huang C, Untch M, Wolmark N, Wapnir IL, Yang Y, Conlin AK, Kümmel S, Saghatchian M, DiGiovanna MP, Strunk C, Zimovjanova M, Song C, Liu H, Tesarowski D, Blotner S, Lam LH, Smitt M, Geyer Jr CE. Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis P3-14-01 Poster

  4. Sonnenblick A, Salmon-Divon M, Salgado R, Pondé N, Loibl S, Denkert C, Joensuu H, Kellokumpu-Lehtinen P, Azaria A, Loi S, Michiels S, Sotiriou C. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer P4-10-16 Poster

  5. Jerusalem G, Farah S, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Gombos A, Ruhstaller T, Burstein H, Rabaglio M, Ruepp B, Viale G, Gelber RD, Coates AS, Di Leo A, Goldhirsch A, Regan M, Colleoni M. SOLE Investigators and International Breast Cancer Study Group, Bern, Switzerland. Sole (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (bc): final analysis and sole estrogen substudy (sole-est) P5-12-01 Poster

  6. Dejan Juric, Fabrice Andre, Christian F. Singer, Joohyuk Sohn, Mario Campone, Sibylle Loibl, Pierfranco Conte, Hiroji Iwata, Eva Ciruelos, Ingrid A. Mayer, Albert Reising, Chong Ma, Michelle Miller, Naveen Babbar and Hope S. Rugo. Clinical outcomes of alpelisib in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer by next-generation sequencing-detected PIK3CA alteration status and phosphatase and tensin homolog loss: Biomarker analysis from the SOLAR-1 study. P4-10-04 Poster

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd